دورية أكاديمية
أعرض في EDS

Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.

التفاصيل البيبلوغرافية
العنوان: Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.
المؤلفون: Malandro N; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA., Budhu S; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Kuhn NF; Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Liu C; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Murphy JT; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA., Cortez C; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Zhong H; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Yang X; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Rizzuto G; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA., Altan-Bonnet G; Programs in Computational Biology & Immunology, Memorial Sloan Kettering, New York, NY 10065, USA., Merghoub T; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: merghout@mskcc.org., Wolchok JD; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: wolchokj@mskcc.org.
المصدر: Immunity [Immunity] 2016 Jan 19; Vol. 44 (1), pp. 179-193.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 9432918 Publication Model: Print Cited Medium: Internet ISSN: 1097-4180 (Electronic) Linking ISSN: 10747613 NLM ISO Abbreviation: Immunity Subsets: MEDLINE
أسماء مطبوعة: Publication: Cambridge, MA : Cell Press
Original Publication: Cambridge, Mass. : Cell Press, c1994-
مواضيع طبية MeSH: CD4-Positive T-Lymphocytes/*immunology , Melanoma, Experimental/*immunology , Tumor Escape/*immunology, Adoptive Transfer ; Animals ; Cell Separation ; Flow Cytometry ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout
مستخلص: Current approaches to cancer immunotherapy aim to engage the natural T cell response against tumors. One limitation is the elimination of self-antigen-specific T cells from the immune repertoire. Using a system in which precursor frequency can be manipulated in a murine melanoma model, we demonstrated that the clonal abundance of CD4(+) T cells specific for self-tumor antigen positively correlated with antitumor efficacy. At elevated precursor frequencies, intraclonal competition impaired initial activation and overall expansion of the tumor-specific CD4(+) T cell population. However, through clonally derived help, this population acquired a polyfunctional effector phenotype and antitumor immunity was enhanced. Conversely, development of effector function was attenuated at low precursor frequencies due to irreversible T cell exhaustion. Our findings assert that the differential effects of T cell clonal abundance on phenotypic outcome should be considered during the design of adoptive T cell therapies, including use of engineered T cells.
(Copyright © 2016 Elsevier Inc. All rights reserved.)
References: J Exp Med. 1998 Dec 21;188(12):2205-13. (PMID: 9858507)
J Exp Med. 2009 Apr 13;206(4):849-66. (PMID: 19332877)
J Immunol. 2003 Jul 1;171(1):240-6. (PMID: 12817004)
Blood. 2008 Jul 15;112(2):362-73. (PMID: 18354038)
Immunity. 2007 Jun;26(6):827-41. (PMID: 17555991)
Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12063-8. (PMID: 16880405)
J Exp Med. 2010 Mar 15;207(3):637-50. (PMID: 20156971)
Nat Rev Immunol. 2013 Nov;13(11):777-89. (PMID: 24113868)
J Exp Med. 1993 Apr 1;177(4):925-35. (PMID: 7681471)
J Virol. 2005 Aug;79(16):10514-27. (PMID: 16051844)
Immunity. 2000 Dec;13(6):783-94. (PMID: 11163194)
Nature. 2006 Feb 9;439(7077):682-7. (PMID: 16382236)
Cancer Cell. 2015 Apr 13;27(4):450-61. (PMID: 25858804)
Immunity. 2007 Aug;27(2):203-13. (PMID: 17707129)
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15045-50. (PMID: 17827281)
Immunity. 2006 Aug;25(2):261-70. (PMID: 16879996)
J Exp Med. 1994 Jul 1;180(1):1-4. (PMID: 8006576)
J Immunol. 2006 Mar 1;176(5):3037-43. (PMID: 16493062)
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3312-7. (PMID: 21292989)
Immunity. 2000 Sep;13(3):291-301. (PMID: 11021527)
J Exp Med. 2002 Mar 4;195(5):657-64. (PMID: 11877489)
CA Cancer J Clin. 1976 Mar-Apr;26(2):119-21. (PMID: 816431)
J Immunol. 2012 May 1;188(9):4135-40. (PMID: 22517866)
Nature. 1992 Nov 19;360(6401):266-8. (PMID: 1279442)
J Exp Med. 2010 Mar 15;207(3):651-67. (PMID: 20156973)
Nat Rev Immunol. 2004 Aug;4(8):595-602. (PMID: 15286726)
Science. 2006 Apr 7;312(5770):114-6. (PMID: 16513943)
J Exp Med. 2010 Jan 18;207(1):223-35. (PMID: 20065066)
J Exp Med. 2006 Apr 17;203(4):1045-54. (PMID: 16567390)
Science. 2012 Nov 30;338(6111):1220-5. (PMID: 23197535)
Cancer Res. 2005 Feb 1;65(3):1089-96. (PMID: 15705911)
Virology. 2010 Feb 20;397(2):260-9. (PMID: 19962171)
Nat Immunol. 2005 Aug;6(8):793-9. (PMID: 16025119)
Nat Immunol. 2011 May 29;12(7):663-71. (PMID: 21623380)
PLoS Pathog. 2014 Jul 17;10(7):e1004251. (PMID: 25032686)
Blood. 2011 May 26;117(21):5582-90. (PMID: 21403129)
J Exp Med. 2000 Oct 16;192(8):1105-13. (PMID: 11034600)
J Immunol. 2006 Mar 1;176(5):3028-36. (PMID: 16493061)
Immunity. 2014 Feb 20;40(2):289-302. (PMID: 24530057)
معلومات مُعتمدة: R25 CA020449 United States CA NCI NIH HHS; R01-AI083408 United States AI NIAID NIH HHS; P30 CA008748 United States CA NCI NIH HHS; R01-AI116863 United States AI NIAID NIH HHS; R01 CA056821 United States CA NCI NIH HHS; R01CA56821 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20160121 Date Completed: 20160607 Latest Revision: 20240325
رمز التحديث: 20240325
مُعرف محوري في PubMed: PMC4996670
DOI: 10.1016/j.immuni.2015.12.018
PMID: 26789923
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-4180
DOI:10.1016/j.immuni.2015.12.018